This funding is in addition to the existing contract valued at up to $153.2M previously awarded on 9/1/10. Under terms of this revised contract, CTI will receive up to $80M in the 2 year base period of performance and up to an additional $89.9M in 3 option years, if exercised by BARDA, bringing the total value of the contract to $169.9M.
- With the supplemental funding, CTI will expand its ongoing clinical trials by activating additional sites and accelerating its clinical development efforts. CTI’s 1st P1 study is evaluating CLT-008 in patients undergoing cord blood transplants for the treatment of hematological malignancies;
- CLT-008 is intended to rapidly produce neutrophils and platelets in vivo and facilitate long-term engraftment in patients undergoing bone marrow or cord blood transplantation;
- CTI’s 2nd P2/3 study is evaluating CLT-008 in acute leukemia patients with chemotherapy-induced neutropenia. CLT-008 may shorten the time to neutrophil recovery and decrease the risks of febrile neutropenia and infection.
The Bottom Line: In ARS applications, CLT-008 is intended to provide hematopoietic cellular support after exposure to ionizing radiation such as from a nuclear or radiological weapon, or from a nuclear accident. CLT-008 is an off-the-shelf, cryopreserved, cell-based therapy that contains human Myeloid Progenitor Cells derived from adult hematopoietic stem cells that have the ability to mature into functional granulocytes, platelets and red blood cells in vivo. In preclinical models, CLT-008 has been shown to be highly effective in providing protection from lethal radiation, preventing infection, facilitating stem cell engraftment and improving overall survival with a high degree of efficacy. Cellerant Therapeutics is a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer.